Using CT to Measure Heart Fibrosis in Atrial Fibrillation Patients Before Ablation
Official title: 320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.
Run by Johns Hopkins University · NCT06308094 · Data updated 2026-11-12
This study tests if measuring heart tissue changes with a CT scan can help predict how well people with Atrial Fibrillation will do after a heart procedure.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Status | Recruiting |
| Started | April 10, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | April 13, 2026 |
| Trial ID | NCT06308094 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 21 and older with symptomatic paroxysmal or persistent atrial fibrillation who are suitable for ablation.
✕Probably not a fit
Patients with known allergies to iodinated contrast media or those with severe renal impairment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the link between myocardial fibrosis and outcomes in patients with Atrial Fibrillation (AF) undergoing catheter ablation. It utilizes Cardiac CT to measure left ventricular extracellular volume (ECV) as a potential indicator of fibrosis. The research aims to determine if higher ECV levels are associated with increased risks of AF recurrence, hospitalization, and poor recovery of cardiac function. By establishing this relationship, the study could influence treatment strategies for AF based on ECV measurements.
Why it matters
Potential benefit: If successful, this study could help identify patients at higher risk for poor outcomes after AF ablation, leading to more personalized treatment approaches.
How similar studies have gone: While the use of ECV as a prognostic tool in AF is relatively novel, similar studies have shown promise in other cardiac conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be at least 21 years old at the time of enrollment. * Patients must be able to give informed consent. * Patients with symptomatic paroxysmal/persistent atrial fibrillation (AF). * Eligible patients must be determined to be suitable candidates for ablation to treat AF by their cardiologist and/or electrophysiologists regardless of this protocol. * Patients are scheduled to have a pre-procedure cardiac CT upon the discretion of their electrophysiologists Exclusion Criteria: * Known allergy to iodinated contrast media. * Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula). * Patients with a positive urine or serum pregnancy test will be excluded from this study. * Patients with heart transplantation. * Patients with polymorphic ventricular tachycardia (VT) or presenting in electrical storm. * Presence of any other history or condition that the investigator feels would be problematic. * Patient with iodinated contrast administration for other reason 24 hours prior to investigational CT. * Patients who have a heart pacemaker, metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain, mechanical heart valves and prosthetics that contain metal. * Patients with severe claustrophobia.
Where it's running
-
Johns Hopkins Hospital
Baltimore, Maryland, United States Recruiting
Study contacts
- Principal investigator: Konstantinos Aronis, MD, PhD — Johns Hopkins School of Medicine
- Study coordinator: Konstantinos Aronis, MD PHD
- Email: karonis1@jhmi.edu
- Phone: 2017169226
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation
This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.
-
Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II
This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.
-
4D intracardiac echocardiography to guide left atrial appendage occlusion procedures
A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.
-
Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium
This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.